Pipeline

Glactone Pharma’s Project Portfolio

Pipeline June 2019

GPB730
Synthetic analog of galiellalactone (GPA500) with improved potency and selectivity

GPA512
Orally bioavailable prodrug of galiellalactone (GPA500) for the treatment of CRPC

GPA700-BU
Second generation STAT3 inhibitors with improved potency